Can Ki-67 predict recurrence of no squamous cell carcinoma of the tongue?

Annals of Otology, Rhinology and Laryngology

Volumn 115, Issue 1, 2006, Pages 12-17

  Davies, Louise ^a,b   Hardin, Nicholas J ^a   Beatty, Barbara G ^a  

^a FLETCHER ALLEN HEALTH CARE   (United States)

^b VA MEDICAL CENTER   (United States)

Author keywords

Head and neck cancer; Ki 67; Molecular marker; Squamous cell carcinoma

Indexed keywords

KI 67 ANTIGEN; MOLECULAR MARKER;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER RECURRENCE; CELL PROLIFERATION; CLINICAL ARTICLE; COHORT ANALYSIS; DISEASE ASSOCIATION; FEMALE; HEAD AND NECK TUMOR; HISTOPATHOLOGY; HUMAN; MALE; OROPHARYNX CANCER; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; RETROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; SURVIVAL TIME; TONGUE CARCINOMA; TUMOR CELL;

EID: 31144455658     PISSN: 00034894     EISSN: None     Source Type: Journal    
DOI: 10.1177/000348940611500102     Document Type: Article

References (15)

1. Zhang XD, Coventry BJ, Jamieson GG, Gill PG. The utility of the proliferative index in pretreatment biopsy specimens of esophageal squamous cell carcinoma. Dis Esophagus 1998;11:215-20.
2. Chino O, Makuuchi H, Shimada H, Machimura T, Mitomi T, Osamura RY. Assessment of the proliferative activity of superficial esophageal carcinoma using MIB-1 immunostaining for the Ki-67 antigen. J Surg Oncol 1998;67:18-24.
3. Pulkkinen JO, Penttinen M, Jalkanen M, Klemi P, Grenman R. Syndecan-1: a new prognostic marker in laryngeal cancer. Acta Otolaryngol (Stockh) 1997;117:312-5.
4. Krecicki T, Jelen M, Zalesska-Krecicka M, Rak J, Szkudlarek T, Jelen-Krzeszewska J. Epidermal growth factor receptor (EGFR), proliferating cell nuclear antigen (PCNA) and Ki-67 antigen in laryngeal epithelial lesions. Oral Oncol 1999;35:180-6.
5. Hagedorn HG, Tubel J, Wiest I, Nerlich AG. In situ apoptotic and proliferation index in laryngeal squamous cell carcinomas. Analyt Cell Pathol 1998;16:177-84.
6. Valente G, Giusti U, Kerim S, et al. High prognostic impact of growth fraction parameters in advanced stage laryngeal squamous cell carcinoma. Oncol Rep 1999;6:289-93.
7. Krecicki T, Jelen M, Zalesska-Krecicka M, Szkudlarek T. Ki-67 immunostaining and prognosis in laryngeal cancer. Clin Otolaryngol Allied Sci 1998;23:539-42.
8. Pignataro L, Capaccio P, Pruneri G, et al. The predictive value of p53, MDM-2, cyclin D1 and Ki67 in the progression from low-grade dysplasia towards carcinoma of the larynx. J LaryngolOtol 1998;112:455-9.
9. Golusinski W, Olofsson J, Szmeja Z, Biczysko W, Krygier-Stojalowska A, Kulczynski B. A comprehensive analysis of selected diagnostic methods with respect to their usefulness in evaluating the biology of neoplastic cells in patients with laryngeal cancer. Eur Arch Otorhinolaryngol 1999;256:306-11.
10. Matsumoto M, Komiyama K, Okaue M, et al. Predicting tumor metastasis in patients with oral cancer by means of the proliferation marker Ki67. J Oral Sci 1999;41:53-6.
11. Gonzales-Moles MA, Caballero R, Rodriguez-Archilla A, Ruiz-Avila I, Bravo I. Prognosis value of the expression of Ki-67 for squamous cell carcinoma of the oral cavity. Acta Stomatol Belg 1996;93:159-65.
12. Nylander K, Schildt EB, Erikkson M, Roos G. PCNA, Ki-67, p53, bcl-2 and prognosis in intraoral squamous cell carcinoma of the head and neck. Analyt Cell Pathol 1997;14:101-10.
13. Jacob R, Welkoborsky HJ, Mann WJ, Hofken F, Dienes HP, Freije JE. Heterogeneity of squamous cell carcinomas of the head and neck - analysis of tumor biologic factors and proliferation rates. Laryngoscope 1996;106:1170-5.
14. Piffko J, Bankfalvi J, Ofner D, et al. In situ assessment of cell proliferation at the invasive front of oral squamous cell carcinomas. Virchows Arch 1996;429:229-34.
15. Brown DC, Gatter KC. Monoclonal antibody Ki-67: its use in histopathology. Histopathology 1990;17:489-503.